Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Patients with advanced hepatocellular carcinoma are treated using conventional therapeutic approaches and a variety of molecularly targeted drugs. Nevertheless, therapeutic resistance emerges because of the high heterogeneity of the malignancy, often restricting the effectiveness of these interventions. Therefore, therapeutic resistance represents a significant obstacle in managing liver cancer. Ubiquitination and deubiquitination, essential regulatory mechanisms, regulate the activity of diverse proteins and are pivotal in determining tumor therapeutic resistance. In this review, we focus on the enzymes involved in ubiquitination and deubiquitination in hepatocellular carcinoma, examining their associated phenotypes. Furthermore, we synthesize findings from a range of studies to elucidate the mechanisms of therapeutic resistance in hepatocellular carcinoma and highlight the critical role of ubiquitination and deubiquitination enzymes in these processes. Finally, we explore the therapeutic potential of targeting the ubiquitination and deubiquitination systems to enhance drug efficacy in liver cancer treatment significantly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-025-02912-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic cell death in cancer: mechanisms and therapeutic potential.
Apoptosis
September 2025
School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
A defining hallmark of malignant tumours lies in their pronounced resistance to programmed cell death mechanisms. This intrinsic resilience enables cancer cells to circumvent physiological clearance, thereby sustaining unchecked proliferation and survival. Emerging research has revealed that metabolic dysregulation can precipitate a distinctive form of programmed cell death, termed metabolism-linked regulated cell death (RCD), establishing it as a novel paradigm of cellular self-elimination.
View Article and Find Full Text PDFStatins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.
CNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFTargeting the tumor microenvironment in colorectal cancer: the effect of Rapamycin on angiogenesis, apoptosis, and STAT5A/TORC1 signaling.
Mol Biol Rep
September 2025
Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.
Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. The tumor microenvironment (TME), particularly the interactions between endothelial cells and cancer-associated fibroblasts (CAFs), plays a pivotal role in promoting tumor growth, angiogenesis, oxidative stress, and therapy resistance. The HUVEC-fibroblast co-culture model closely mimics stromal-endothelial interactions observed in CRC, enabling mechanistic insights not achievable in monocultures.
View Article and Find Full Text PDFExploring LRP-1 in the liver-brain axis: implications for Alzheimer's disease.
Mol Biol Rep
September 2025
Department of Pharmacology, Govt. College of Pharmacy, Rohru, Shimla, Himachal Pradesh, 171207, India.
Alzheimer's disease (AD) is the most common, complex, and untreatable form of dementia which is characterized by severe cognitive, motor, neuropsychiatric, and behavioural impairments. These symptoms severely reduce the quality of life for patients and impose a significant burden on caregivers. The existing therapies offer only symptomatic relief without addressing the underlying silent pathological progression.
View Article and Find Full Text PDFComparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies.
Ann Hematol
September 2025
Excellence Center for Comprehensive Cancer (ECCCC), King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target for novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers (BiTEs), which vary in efficacy, toxicity, and accessibility. To compare the efficacy and safety of BCMA-directed CAR-T therapies and BiTEs in R/R MM through a systematic review and meta-analysis.
View Article and Find Full Text PDF